An Inside Look at the Role of Data Monitoring Committees with Dr. Jonathan Seltzer

 

About this Podcast: 

In this episode, WCG’s President of Patient Advocacy, Steve Smith, interviews Dr. Jonathan Seltzer, MD, Chief Scientific Officer at WCG, expert on data safety monitoring boards, biomarkers, biostatistics, and clinical endpoints.

During their conversation, Steve and Dr. Seltzer discuss how biomarkers are appropriate for the use of trials, especially when clinical data is tough to get.

Part of this discussion turns to Duchenne’s Muscular Dystrophy (an inherited rare muscular disease) on how Patient Advocacy Groups are working with the FDA to define risk vs. benefit, and how promising a biomarker for this condition - as well as many other rare disorders - would be.

About the Author

Steve Smith | President, Patient Advocacy, WCG

Steve Smith is a seasoned patient advocate with an extensive career in software, consulting, process transformation, health care systems and patient-focused drug development. He joined WCG as President Patient Advocacy in 2019 inspired by the incredible value to patients embedded in the wide range of WCG solutions that reduce the time and cost of clinical trials.

Visit Website More Content by Steve Smith | President, Patient Advocacy, WCG
Previous Post
Chasing My Cure: an Interview with Dr. David Fajgenbaum
Chasing My Cure: an Interview with Dr. David Fajgenbaum

Next Post
Biostatistics and Biomarkers for the Reliability and Efficiency of Clinical Trials: A Conversation with Dr. Janet Wittes
Biostatistics and Biomarkers for the Reliability and Efficiency of Clinical Trials: A Conversation with Dr. Janet Wittes